Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry

Simple item page
dc.contributor.authorAkgul O.
dc.contributor.authorBodur H.
dc.contributor.authorAtaman S.
dc.contributor.authorYurdakul F.G.
dc.contributor.authorCapkin E.
dc.contributor.authorGurer G.
dc.contributor.authorSezer I.
dc.contributor.authorDuruoz M.T.
dc.contributor.authorMelikoglu M.A.
dc.contributor.authorCay H.F.
dc.contributor.authorRezvani A.
dc.contributor.authorYagci I.
dc.contributor.authorGogus F.
dc.contributor.authorKamanli A.
dc.contributor.authorCevik R.
dc.date.accessioned2024-07-22T08:07:03Z
dc.date.available2024-07-22T08:07:03Z
dc.date.issued2020
dc.description.abstractThe Assessment of SpondyloArthritis international Society Health Index (ASAS HI) is used as a new instrument in measuring the function, disability and health of patients with spondyloarthritis (SpA). However, the real-world evidence of ASAS HI is very limited. In the present study, our objective is to evaluate the psychometric properties and performance of ASAS HI in the real-world setting as well as comparing ASAS HI with the current instruments to assess the construct validity and determine the cut-off points in patients with both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). A total of 991 patients with axSpA who fulfilled either the ASAS classification criteria for axial SpA (axSpA) or the Modified New York Criteria (mNY) for AS were recruited from the Biologic and targeted Synthetic antirheumatic drugs Registry (BioStaR) SpA. The construct validity of ASAS HI against the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score–C-Reactive Protein (ASDAS-CRP) the Bath Ankylosing Spondylitis Functional index (BASFI) was performed. Using the receiver operating characteristic (ROC) curves analysis, the cut-off points were calculated. Of all the recruited patients, 851 (85.9%) were AS and 140 (14.1%) were nr-axSpA. The difference in the mean ASAS HI scores of the patients with AS and the ones with nr-axSpA were not statistically significant (6.12 ± 4.29 and 6.42 ± 4.86, respectively). The mean ASAS HI score was significantly higher in females and small city residents. The ASAS HI had a strong construct validity against ASDAS-CRP, BASDAI and BASFI. A cut-off point of ≤ 4 was determined to discriminate good and moderate, as well as ≥ 12 to discriminate moderate and poor health status. In conclusion, ASAS HI is a reliable instrument to evaluate health and functioning for both patients with AS and nr-axSpA in clinical practice. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s00296-020-04680-8
dc.identifier.issn01728172
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13799
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectActivities of Daily Living
dc.subjectAdult
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPsychometrics
dc.subjectQuality of Life
dc.subjectRegistries
dc.subjectReproducibility of Results
dc.subjectSpondylarthropathies
dc.subjectSpondylitis, Ankylosing
dc.subjectSurveys and Questionnaires
dc.subjectTurkey
dc.subjectadult
dc.subjectankylosing spondylitis
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectAnkylosing Spondylitis Disease Activity Score C Reactive Protein
dc.subjectArticle
dc.subjectassessment of spondyloarthritis international society classification
dc.subjectAssessment of SpondyloArthritis international Society Health Index
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectBath ankylosing spondylitis functional index
dc.subjectclinical evaluation
dc.subjectcohort analysis
dc.subjectconstruct validity
dc.subjectcross-sectional study
dc.subjectdiscriminant validity
dc.subjectdisease activity
dc.subjectdisease classification
dc.subjectdisease registry
dc.subjectfemale
dc.subjectfunctional status
dc.subjecthealth status
dc.subjecthuman
dc.subjectintermethod comparison
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectModified New York Criteria
dc.subjectmusculoskeletal disease assessment
dc.subjectobservational study
dc.subjectpriority journal
dc.subjectpsychometry
dc.subjectquality of life
dc.subjectquality of life assessment
dc.subjectreference value
dc.subjectreliability
dc.subjectsensitivity and specificity
dc.subjectsex difference
dc.subjectspondylarthritis
dc.subjecturban population
dc.subjectankylosing spondylitis
dc.subjectclinical trial
dc.subjectdaily life activity
dc.subjectdiagnostic imaging
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectpathophysiology
dc.subjectquestionnaire
dc.subjectregister
dc.subjectreproducibility
dc.subjectspondyloarthropathy
dc.subjectturkey (bird)
dc.titleClinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry
dc.typeArticle

Files

Collections

Scopus Koleksiyonu